Cravatex

Why is Cravatex Ltd falling/rising?

As of 31-Aug, Cravatex Ltd's stock price is stable at 323.25 but has declined 12.88% year-to-date and 26.21% over the past year, underperforming the Sensex. Despite a slight increase in investor participation and a high dividend yield of 4.02%, the stock remains below its moving averages, indicating a bearish trend.

As of 31-Aug, Cravatex Ltd's stock price is currently stable at 323.25, showing no change (0.00%). However, the stock has experienced a decline over various periods, with a year-to-date drop of 12.88% and a one-year decrease of 26.21%. This performance is notably worse than the benchmark Sensex, which has only fallen by 9.70% over the same year.<BR><BR>Despite today's performance indicating that Cravatex has outperformed its sector by 0.56%, the stock is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This suggests a bearish trend in the stock's price movement.<BR><BR>On a positive note, there has been a rise in investor participation, with delivery volume increasing by 5.26% compared to the 5-day average. Additionally, the stock boasts a high dividend yield of 4.02%, which may attract some investors. However, the overall trend indicates that Cravatex Ltd is facing challenges, contributing to its declining stock performance over the longer term.

Who are in the management team of Cravatex?

The management team of Cravatex includes Rajesh Batra (Chairman & Managing Director), S D Israni, N Santhanam, and Pheroza Jimmy Bilimoria (Independent Directors), Sudhanshu Namdeo (Company Secretary), Divakar Ganapati Kamath (Executive Director & CFO), and Rohan Batra (Director).

The management team of Cravatex includes the following individuals:<BR><BR>1. **Rajesh Batra** - Chairman & Managing Director<BR>2. **S D Israni** - Independent Director<BR>3. **Sudhanshu Namdeo** - Company Secretary & Compliance Officer<BR>4. **N Santhanam** - Independent Director<BR>5. **Pheroza Jimmy Bilimoria** - Independent Director<BR>6. **Divakar Ganapati Kamath** - Executive Director & CFO<BR>7. **Rohan Batra** - Director<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

What does Cravatex do?

Cravatex Ltd is a micro-cap company in the Trading & Distributors industry, specializing in sports goods and fitness equipment, with a market cap of INR 84 Cr and reported net sales of 32 Cr for June 2026. It operates two subsidiaries and has a P/E ratio of 10.00 and a dividend yield of 4.02%.

Overview:<BR>Cravatex Ltd is a micro-cap company operating in the Trading & Distributors industry, specializing in sports goods and fitness equipment.<BR><BR>History:<BR>Cravatex Ltd was incorporated in 1951 by Ram Kumar Batra. The company is currently the holding entity for two subsidiaries: BB (UK) London and Cravatex Brands Ltd Mumbai. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 32 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 84 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 10.00<BR>- Industry P/E: 21<BR>- Dividend Yield: 4.02%<BR>- Debt Equity: -0.80<BR>- Return on Equity: 5.69%<BR>- Price to Book: 0.70<BR><BR>Contact Details:<BR>Address: Unit-201 2nd Flr Matulya Centr, S B Marg Lower Parel Mumbai Maharashtra : 400013<BR>Email: investors@cravatex.com<BR>Website: http://www.cravatex.com

Who are the peers of the Cravatex?

Cravatex's peers include MRC Agrotech, Mehai Technology, Uma Exports, Goyal Aluminiums, Sharika Enterprises, Variman Global, Confidence Fut., Fervent Synerg., and Ashnisha Indus. Management risks vary, with Mehai Technology rated excellent, while Cravatex and Goyal Aluminiums are average; Cravatex's 1-year return is -26.21%, better than Mehai Technology's -85.31% but worse than Sharika Enterprises' 58.30%.

Peers: The peers of Cravatex are MRC Agrotech, Mehai Technology, Uma Exports, Goyal Aluminiums, Sharika Enterpr., Variman Global, Confidence Fut., Fervent Synerg., and Ashnisha Indus.<BR><BR>Quality Snapshot: Excellent management risk is observed at Mehai Technology, while Average management risk is found at Goyal Aluminiums and Cravatex. Below Average management risk is noted for MRC Agrotech, Uma Exports, Sharika Enterpr., Variman Global, Confidence Fut., Fervent Synerg., and Ashnisha Indus. Growth is Excellent at Mehai Technology, Good at MRC Agrotech, Confidence Fut., and Fervent Synerg., while Average growth is seen at Variman Global. Below Average growth is present in Uma Exports, Goyal Aluminiums, Sharika Enterpr., Ashnisha Indus, and Cravatex. Capital Structure is Excellent at Variman Global, Good at Goyal Aluminiums, and Below Average for the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Sharika Enterpr. at 58.30%, while Mehai Technology has the lowest at -85.31%. Cravatex's 1-year return of -26.21% is better than Mehai Technology's but worse than Sharika Enterpr.'s. Additionally, the six-month returns for MRC Agrotech, Variman Global, Confidence Fut., Fervent Synerg., and Ashnisha Indus. are all negative.

How big is Cravatex?

As of 31st August, Cravatex Ltd has a market capitalization of 84.00 Cr, with net sales of 159.97 Cr and a net profit of 8.61 Cr over the latest four quarters. The balance sheet for March 2026 shows shareholder's funds of 119.44 Cr and total assets of 146.20 Cr.

As of 31st August, Cravatex Ltd has a market capitalization of 84.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Cravatex reported net sales of 159.97 Cr and a net profit of 8.61 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, showing shareholder's funds of 119.44 Cr and total assets of 146.20 Cr.

Which are the latest news on Cravatex?

Should I buy, sell or hold Cravatex Ltd?

Are Cravatex Ltd latest results good or bad?

Cravatex Ltd's latest results are largely negative, showing a net profit increase of 11.11% to ₹1.60 crores, but a significant 34.72% decline in net sales to ₹39.51 crores and a negative operating margin of -1.52% indicate serious operational challenges. The company's reliance on non-operating income raises concerns about the sustainability of its profitability.

Cravatex Ltd's latest results present a mixed picture, but overall, they lean towards the negative side. In Q4 FY26, the company reported a net profit of ₹1.60 crores, which is an increase of 11.11% year-on-year. However, this positive aspect is overshadowed by a significant decline in net sales, which fell by 34.72% to ₹39.51 crores compared to the same quarter last year.<BR><BR>While the profit after tax (PAT) margin improved to 4.05% from 2.38% year-on-year, the operating margin turned negative at -1.52%, a sharp decline from the previous year's positive margin. This indicates that the core operational performance is struggling, as the company generated an operating loss of ₹0.60 crores before accounting for other income.<BR><BR>Moreover, the reliance on non-operating income is concerning, as it constituted a staggering 147.32% of profit before tax, highlighting a dependency that raises questions about the sustainability of profitability. The overall financial health is further complicated by a five-year sales growth rate of -19.56%, indicating a long-term trend of revenue contraction.<BR><BR>In summary, while there are some improvements in profit margins, the sharp decline in sales and operational losses signal significant challenges for Cravatex Ltd, making the latest results more negative than positive.

How has been the historical performance of Cravatex?

Cravatex has experienced significant declines in net sales and profitability, with net sales dropping from 594.33 Cr in Mar'22 to 173.76 Cr in Mar'25, and operating profit margins turning negative. Despite a reduction in total liabilities, the company has struggled to maintain revenue and profitability over recent years.

Answer:<BR>The historical performance of Cravatex shows significant fluctuations in its financial metrics over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Cravatex's net sales have seen a downward trend from 594.33 Cr in Mar'22 to 173.76 Cr in Mar'25, indicating a substantial decline in revenue. The total operating income followed a similar pattern, decreasing from 778.67 Cr in Mar'20 to 173.76 Cr in Mar'25. The company's operating profit margins have been negative in recent years, with an operating profit of -1.69 Cr in Mar'25, compared to a positive 11.30 Cr in Mar'22. Profit before tax also dropped significantly from 58.33 Cr in Mar'23 to 6.37 Cr in Mar'25, while profit after tax remained stagnant at 4.83 Cr for both Mar'25 and Mar'24, down from 58.93 Cr in Mar'23. On the balance sheet, total liabilities decreased from 441.91 Cr in Mar'20 to 140.70 Cr in Mar'25, reflecting a reduction in long-term borrowings, which were eliminated by Mar'25. Total assets also decreased from 441.91 Cr in Mar'20 to 140.70 Cr in Mar'25, with cash and cash equivalents showing a slight increase to 75.45 Cr in Mar'25 from 56.32 Cr in Mar'23. Overall, Cravatex has faced challenges in maintaining revenue and profitability, while managing its liabilities effectively.

When is the next results date for Cravatex?

The next results date for Cravatex is 14 November 2025.

The next results date for Cravatex is scheduled for 14 November 2025.

Is Cravatex overvalued or undervalued?

As of April 25, 2023, Cravatex is considered a risky investment due to its overvaluation, reflected in a PE ratio of 23.05, negative ROCE of -21.02%, and unfavorable comparisons to peers, despite a recent stock return of 11.28%.

As of 25 April 2023, Cravatex's valuation grade has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, with a PE ratio of 23.05, a Price to Book Value of 1.04, and a concerning ROCE of -21.02%. <BR><BR>When compared to peers, Cravatex's valuation stands out unfavorably; for instance, MMTC has a PE ratio of 119.39, while PTC India is valued attractively at a PE of 9.02. The negative EV to EBIT and EV to EBITDA ratios of -6.24 and -11.70, respectively, further underscore the company's financial struggles. Despite a recent stock return of 11.28% over the past month, which outperformed the Sensex's 3.86%, the overall indicators suggest that Cravatex is not a favorable investment at its current price of 439.00.

What is the technical trend for Cravatex?

As of April 28, 2025, Cravatex's technical trend is mildly bearish, influenced by mixed signals from moving averages and indicators, with weekly MACD and Bollinger Bands showing mild bullishness while monthly indicators reflect bearishness.

As of 28 April 2025, the technical trend for Cravatex has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands on the weekly chart are mildly bullish, but the monthly view is bearish. Daily moving averages are mildly bearish, and the KST is mildly bullish on the weekly but bearish on the monthly. Dow Theory reflects a mildly bearish trend on the weekly and no trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the mixed signals from the moving averages and the monthly indicators.

Who are the top shareholders of the Cravatex?

The top shareholder of Cravatex is R B Fitness And Trading Private Limited, holding 74.36% of the shares. Individual investors own 21.13%, while the highest public shareholder is Mahesh Parameswaran Nair with 2.01%.

The top shareholders of Cravatex are primarily the promoters, with R B Fitness And Trading Private Limited holding the largest stake at 74.36%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not hold any shares in the company. The highest public shareholder is Mahesh Parameswaran Nair, who owns 2.01%. Additionally, individual investors collectively hold 21.13% of the shares.

What is the bonus history of the Cravatex?

Cravatex Ltd had a bonus issue of 1:1 announced on July 15, 2011, with a record date of July 19, 2011, allowing shareholders to receive one additional share for each share held.

Cravatex Ltd has a bonus history that includes a 1:1 bonus issue announced on July 15, 2011. The record date for this bonus was July 19, 2011. This means that shareholders received one additional share for every share they held as of the record date.

Has Cravatex declared dividend?

Cravatex Ltd has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of July 30, 2024. The company has shown strong long-term growth, achieving a total return of 62.43% over the past five years.

Cravatex Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: Jul-30-2024<BR><BR>Dividend Yield: 0.7%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Cravatex experienced a price return of -2.99% with no dividend return, resulting in a total return of -2.99%.<BR><BR>Over the past year, the company had a price return of 6.39% and a dividend return of 0.75%, leading to a total return of 7.14%.<BR><BR>In the 2-year period, Cravatex achieved a price return of 44.52% and a dividend return of 1.08%, culminating in a total return of 45.6%.<BR><BR>For the 3-year period, the price return was 15.36% with a dividend return of 2.34%, resulting in a total return of 17.7%.<BR><BR>In the last 4 years, Cravatex saw a price return of 47.98% and a dividend return of 3.48%, giving a total return of 51.46%.<BR><BR>Over the 5-year period, the company recorded a price return of 58.5% along with a dividend return of 3.93%, resulting in a total return of 62.43%.<BR><BR>Overall, Cravatex has declared a significant dividend, and while the recent total returns show variability, the long-term performance indicates strong growth, particularly over the 5-year period.